Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study.
Mahil SK, Bechman K, Raharja A, Domingo-Vila C, Baudry D, Brown MA, Cope AP, Dasandi T, Graham C, Khan H, Lechmere T, Malim MH, Meynell F, Pollock E, Sychowska K, Barker JN, Norton S, Galloway JB, Doores KJ, Tree T, Smith CH. Mahil SK, et al. Among authors: pollock e. Lancet Rheumatol. 2022 Jan;4(1):e42-e52. doi: 10.1016/S2665-9913(21)00333-7. Epub 2021 Nov 9. Lancet Rheumatol. 2022. PMID: 34778846 Free PMC article.
The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study.
Mahil SK, Bechman K, Raharja A, Domingo-Vila C, Baudry D, Brown MA, Cope AP, Dasandi T, Graham C, Lechmere T, Malim MH, Meynell F, Pollock E, Seow J, Sychowska K, Barker JN, Norton S, Galloway JB, Doores KJ, Tree TIM, Smith CH. Mahil SK, et al. Among authors: pollock e. Lancet Rheumatol. 2021 Sep;3(9):e627-e637. doi: 10.1016/S2665-9913(21)00212-5. Epub 2021 Jul 8. Lancet Rheumatol. 2021. PMID: 34258590 Free PMC article.
Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer.
McKenzie DR, Muñoz-Ruiz M, Monin L, Alaguthurai T, Lechmere T, Abdul-Jawad S, Graham C, Pollock E, Graham R, Sychowska K, Seow J, Tremain C, Gousis C, Domingo-Vila C, Cooper J, Vidler J, Owczarczyk K, Swampillai A, Kristeleit H, Malim MH, Fields P, Patten PEM, Papa S, North BV, Tree T, Doores KJ, Hayday AC, Irshad S. McKenzie DR, et al. Among authors: pollock e. Cancer Cell. 2021 Nov 8;39(11):1445-1447. doi: 10.1016/j.ccell.2021.10.003. Epub 2021 Oct 12. Cancer Cell. 2021. PMID: 34678151 Free PMC article. No abstract available.
Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer.
McKenzie DR, Graham R, Lechmere T, Domingo-Vila C, Alaguthurai T, Arman C, Pollock E, Gousis C, Kakkassery H, Carpenter E, Kurshan A, Vidler J, Kulasekararaj A, Patten P, North BV, Tree T, Doores KJ, Hayday AC, Irshad S. McKenzie DR, et al. Among authors: pollock e. Cancer Res Commun. 2022 Nov 17;2(11):1449-1461. doi: 10.1158/2767-9764.CRC-22-0298. Cancer Res Commun. 2022. PMID: 36824220 Free PMC article.
Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
Cappuccini F, Bryant R, Pollock E, Carter L, Verrill C, Hollidge J, Poulton I, Baker M, Mitton C, Baines A, Meier A, Schmidt G, Harrop R, Protheroe A, MacPherson R, Kennish S, Morgan S, Vigano S, Romero PJ, Evans T, Catto J, Hamdy F, Hill AVS, Redchenko I. Cappuccini F, et al. Among authors: pollock e. J Immunother Cancer. 2020 Jun;8(1):e000928. doi: 10.1136/jitc-2020-000928. J Immunother Cancer. 2020. PMID: 32591433 Free PMC article. Clinical Trial.
174 results